
Purpose:Cancer-related fatigue is a prevalent, debilitating condition that can persist for months or years after treatment. In a single-arm clinical trial, the feasibility and safety of a time-restricted eating (TRE) intervention were evaluated among cancer survivors, and initial estimates of within-person change in cancer-related fatigue were obtained. Methods:Participants were 4-60 months post-cancer treatment, were experiencing fatigue (≥ 3 on a scale 0-10), and were not following TRE. TRE entailed limiting all food and beverages to a self-selected 10-h window for 14 days. Participants reported their eating window in a daily diary and completed the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Brief Fatigue Inventory (BFI), and symptom inventory pre- and post-intervention. This study was pre-registered at clinicaltrials.gov in January 2020 (NCT04243512). Results:Participants (n=39) were 61.5 ± 12.4 years old and 1.8 ± 1.3 years post-treatment; 89.7% had had breast cancer. The intervention was feasible in that 36/39 (92.3%) of participants completed all questionnaires and daily diaries. It was also safe with no severe adverse events or rapid weight loss (average loss of 1.1 ± 2.3 pounds, p=0.008). Most adhered to TRE; 86.1% ate within a 10-h window at least 80% of the days, and the average eating window was 9.33 ± 1.05 h. Fatigue scores improved 5.3 ± 8.1 points on the FACIT-F fatigue subscale (p<0.001, effect size [ES]=0.55), 30.6 ± 35.9 points for the FACIT-F total score (p<0.001, ES=0.50), and -1.0 ± 1.7 points on the BFI (p<0.001, ES=-0.58). Conclusion:A 10-h TRE intervention was feasible and safe among survivors, and fatigue improved with a moderate effect size after two weeks. Limitations:This was a single-arm study, so it is possible that expectation effects were present for fatigue outcomes, independent of effects of TRE per se. However, this feasibility trial supports evaluation of TRE in randomized controlled trials to address persistent cancer-related fatigue.
Medical cancer treatment has evolved in a geometric manner since Gilman´s Mechlorethamine introduction into the bedside. Chemotherapy was born and rapidly proved its worth in different tumors and different clinical settings. Initially, the bright results were seen in hematologic malignancies, namely complete remissions in some types of leukemias and lymphomas and posteriorly in solid tumors, it changed the natural disease history in osteosarcoma, becoming adjuvant methotrexate the new overall survival drug in this malignancy. Many pediatric and young adults’ tumors comported complete remissions with chemotherapy, rendering them as curable diseases. As this, testicular cancer became the first example of a curable cancer model within advanced solid tumors (Cisplatin was the gladiator here). Even when the first clinical trial became from the sixties, during the seventies Oncologists became interested in the after-surgery chemo in breast cancer. Two pivotal trials (the US and Europe), continue showing that even nearly 40 years after, the overall survival benefit of adjuvant chemo in this disease is impressive. As many as with chemo, hormonotherapy proved and continues to prove its worth in postmenopausal breast cancer women. Adding to the before, two milestones in chemo history are the role of chemo in larynx organ preservation and its positive role in the colorectal cancer adjuvant setting. Taking as a profit chemo radio sensitizer power, the role of concomitant chemotherapy and radiotherapy came up to age: Head neck, rectal cancer, anal cancer only to mention some tumor topographies amenable to this combined approach with organ preservation objectives.
It is often difficult to accurately detect with the naked eye whether it is a benign or a malignant change. For this reason you should consult your doctor as soon as possible so the site can be examined. He or she must then decide whether you can wait and observe the area or whether a sample is already necessary for histological examination. In case of doubt it’s better to take a sample once too often than to be sorry. UVR exposure and therefore the extent of an individual’s skin sensitivity to UVR are the most determinants of carcinoma risk. Those with UVR-sensitive skin types are typically fair skinned and have a propensity to sunburn, blister, and/or freckle on exposure to UVR, indicators of enhanced susceptibility to UVR’s skin-damaging effects. For a given level of UVR exposure, skin cancer risk is highest in fair-skinned UVR-sensitive phenotypes, whereas darker skin colors have a more inherent photo protective capacity because of greater levels of melanin.
Statement of the Problem: Red blood cells (RBCs) are the most frequently transfused blood labile product. The “Donorvariation effect”, which refers to donor-todonor differences observed in both blood storage quality and 24h recovery, is probably a key factor in the efficiency of transfusion therapy. Donor variation effect may be associated with genetically determined features of RBCs and plasma. The aim of this study was to examine whether thedonor’s sex may independently affect the storage capacity of donated RBCs. Methodology & Theoretical Orientation: For this purpose, 14 leukoreduced units of RBC concentrates in CPD/SAGM (7 male–7 female) were stored for 42 days at 4-6oC. Several parameters of storage quality (including hemolysis, redox status etc) were examined before and throughout the storage period. SPSS was used for statistical analysis of the results.